Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer

CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that Henry Pelish, Ph.D., has been promoted to Chief Scientific Officer. In this role, Dr. Pelish will continue to oversee discovery and early-stage development activities. Dr. Pelish contributed to the creation of Nuvalent and joined as Biology lead in 2018, overseeing the di ...